Herpes vax safe in early trials
Interim results of the trial showed the vaccine, based on new technology, was safe in 20 Brisbane patients who received three doses via intradermal injection.
Along with the primary endpoint of safety and a positive antibody response, the study also found the vaccine generates a T cell response to eradicate the virus.
All participants were screened to exclude previous exposure to HSV-1 or HSV-2 to ensure they had no antibodies or T cells targeting the virus.
Professor Frazer said the results were “very encouraging”.
“We believe we should progress these programs forward,” he said.?“Once we complete our analysis the team will be looking to take this program into a second clinical study in patients infected with the herpes virus”.
Analysis of the results is ongoing and further data is expected to be released later this year.
If successful, the vaccine technology could also